STAGE IV BREAST CANCER AJCC V6 AND V7
Clinical trials for STAGE IV BREAST CANCER AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV BREAST CANCER AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE IV BREAST CANCER AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 adults…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
New combo therapy zaps spine tumors before they paralyze
Disease control OngoingThis study tests a combination of two treatments—heat-based tumor destruction (thermal ablation) and precise high-dose radiation (stereotactic radiosurgery)—for people whose cancer has spread to the spine and is pressing on the spinal cord. The goal is to control the tumor and pr…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
Breast cancer drug showdown: which hormone therapy works better?
Disease control OngoingThis study tests two hormone therapies, tamoxifen and a newer drug called z-endoxifen, in postmenopausal women with a type of advanced breast cancer (ER+/HER2-). The goal is to see which one better delays cancer growth. About 81 women who have already tried an aromatase inhibitor…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:35 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis early-stage trial tests a combination of two drugs, cyclophosphamide and veliparib, in 35 people with HER2-negative breast cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see how well the drugs work together to stop tumor growt…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New drug cocktail trial aims to tame tough tumors
Disease control OngoingThis early-phase trial tests the safety and best doses of two drugs (bevacizumab and temsirolimus) given alone or with other medicines (valproic acid or cetuximab) in people with advanced cancer or certain non-cancerous diseases that are hard to treat. The goal is to find the hig…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug Z-Endoxifen shows promise in early breast cancer trial
Disease control OngoingThis early-phase trial tested a drug called Z-endoxifen in 62 women with estrogen receptor-positive (ER+) breast cancer that had spread or come back. The main goal was to find the safest dose and understand side effects. Z-endoxifen works by blocking estrogen, which can fuel brea…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
Triple therapy shows promise for stage IV breast cancer
Disease control OngoingThis study tested whether adding an immunotherapy drug (pembrolizumab) to standard hormone therapy (letrozole) and a targeted drug (palbociclib) could shrink tumors in postmenopausal women with newly diagnosed stage IV estrogen receptor-positive breast cancer. The 47 participants…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for hard-to-treat cancers? drug targets tumors with unstable genes
Disease control OngoingThis study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Could a drug combo shrink Hard-to-Treat breast tumors?
Disease control OngoingThis early-phase study tests a new combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 44 adults with advanced or returning breast cancer w…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New scan may predict hormone therapy response in advanced breast cancer
Diagnosis OngoingThis study tests whether a special PET scan called FES can predict how well hormone therapy will work in people with newly diagnosed breast cancer that has spread. About 99 participants will get the scan, which uses a radioactive form of estrogen to "light up" cancer cells. The g…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated May 13, 2026 16:00 UTC
-
New imaging method could reveal how well hormone therapy works in breast cancer
Knowledge-focused OngoingThis study tests a special PET scan called FES PET/CT to see how breast cancer tumors respond to hormone therapy. It involves 2 adults with estrogen receptor-positive breast cancer that is new, has come back, or spread. The scan measures changes in hormone receptor levels before,…
Matched conditions: STAGE IV BREAST CANCER AJCC V6 AND V7
Phase: PHASE2 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 17, 2026 05:47 UTC